A multicenter, randomized, double-blind, placebo (PBO)-controlled, phase III trial of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) in China-MedSci.cn

A multicenter, randomized, double-blind, placebo (PBO)-controlled, phase III trial of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) in China

Gao, M; Ge, M; Xu, Z; Ji, Q; Shi, F; Qin, J; Wang, F; Chen, G; Zhang, Y; Huang, R; Tan, J; Huang, T; Li, S; Lv, Z; Lin, Y; Guo, Z; Kubota, T; Suzuki, T; Ikezawa, H; Zheng, X

ANNALS OF ONCOLOGY, 2020; 31 (): S1407

科室
- - 订阅+
  - 更多科室
工具
服务